FDA Establishes Controls on Polymorphic Substances
This article was originally published in The Gold Sheet
Executive Summary
Polymorphic guidance addresses need to control multi-form drugs.
You may also be interested in...
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says
FDA also should more fully explore using alternatives to on-site inspections the pandemic prevents it from conducting, said Mary Denigan-Macauley, director of GAO’s health care office.
US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: